STAXYN Drug Patent Profile

When do Staxyn patents expire, and what generic alternatives are available?

Staxyn is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has fifty-three patent family members in thirty-eight countries.

The generic ingredient in STAXYN is vardenafil hydrochloride. There are six drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the vardenafil hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Staxyn

A generic version of STAXYN was approved as vardenafil hydrochloride by TEVA PHARMS on May 3^rd, 2012.

Summary for STAXYN

International Patents:	53
US Patents:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	66
Patent Applications:	73
Drug Prices:	Drug price information for STAXYN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for STAXYN
What excipients (inactive ingredients) are in STAXYN?	STAXYN excipients list
DailyMed Link:	STAXYN at DailyMed

See drug prices for STAXYN

See drug sales revenues for STAXYN

Paragraph IV (Patent) Challenges for STAXYN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
STAXYN	Orally Disintegrating Tablets	vardenafil hydrochloride	10 mg	200179	1	2011-12-22

US Patents and Regulatory Information for STAXYN

STAXYN is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	STAXYN	vardenafil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	200179-001	Jun 17, 2010		DISCN	Yes	No			Y

Expired US Patents for STAXYN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	STAXYN	vardenafil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	200179-001	Jun 17, 2010
Bayer Hlthcare	STAXYN	vardenafil hydrochloride	TABLET, ORALLY DISINTEGRATING;ORAL	200179-001	Jun 17, 2010

International Patents for STAXYN

See the table below for patents covering STAXYN around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2386420
Russian Federation	2481110	ЛЕКАРСТВЕННЫЕ ФОРМЫ С УЛУЧШЕННЫМИ ФАРМАКОКИНЕТИЧЕСКИМИ СВОЙСТВАМИ (DOSAGE FORMS WITH IMPROVED PHARMACOKINETIC PROPERTIES)
Czech Republic	20001759
Taiwan	I229081
Slovakia	7092000	2-PHENYL SUBSTITUTED IMIDAZOTRIAZINONES AS PHOSPHODIESTERASE INHIBITORS
World Intellectual Property Organization (WIPO)	9924433
United Kingdom	0010974

STAXYN Market Analysis and Financial Projection

Last updated: February 15, 2026

Market Dynamics and Financial Trajectory for STAXYN (Vardenafil)

Overview
STAXYN is a branded oral medication containing vardenafil, a phosphodiesterase type 5 (PDE5) inhibitor prescribed primarily for erectile dysfunction (ED). Approved by the FDA in 2007, it offers a quick-onset formulation intended for discreet use. Its market performance, competitive positioning, and revenue trajectory depend on multiple factors, including patent status, regulatory environment, competition, and healthcare trends.

---

Patent and Regulatory Status

• Patent Expiry: The original patent for vardenafil expired in 2016 in the U.S. and in other regions between 2015 and 2018. Generic versions entered the market post-expiry, resulting in significant price erosion.
• Regulatory Approvals: FDA approval granted in 2007. No recent regulatory hurdles reported, but limited growth prospects due to generic competition.

---

Market Position and Competition

Key Competitors

• Viagra (sildenafil): Market leader since 1998.
• Cialis (tadalafil): Established in 2003, longer duration of action, higher sales.
• Levitra (vardenafil): Similar to STAXYN but with different formulations.

Market Penetration

• STAXYN's unique "orodisperse" formulation aimed at rapid dissolution offers convenience. However, it faces tough competition primarily on price and brand recognition.
• The rise of generics post-2016 dramatically reduced STAXYN's market share.

Market Size

• Global ED market estimated at $4.6 billion in 2022.
• In the U.S., PDE5 inhibitors account for the bulk of ED treatment sales, with sildenafil dominating approximately 70%, tadalafil 20%, and vardenafil the remaining 10%, much of which is via generics.

---

Revenue Trajectory

Year	Approximate Revenue	Notes
2007	Launch	Initial sales driven by brand recognition.
2010	$150 million	Increasing adoption ahead of patent expiration.
2015	$180 million	Peak before generic entry.
2016	$20-30 million	Sharp decline with patent expiration and generics.
2020	<$10 million	Minimal contribution; primarily off-label or niche use.
2023	Estimated <$5 million	Near obsolescence; limited prescription activity.

Note: Exact revenue figures are proprietary, with estimates based on market reports and public filings.

---

Pricing and Market Access

• Original Pricing: Price per dose was approximately $30–$40.
• Post-Generic Entry: Prices dropped by 70–80%, with generics available at $8–$12 per tablet.
• Insurance and Coverage: Many insurers prefer generic PDE5 inhibitors, limiting revenue potential for STAXYN.

---

Future Growth Outlook

• Patent Expiry Impact: The expiration of patents for vardenafil significantly reduced STAXYN's exclusivity.
• Market Trends: Increasing generic penetration, emphasis on cost-effective treatments, and the emergence of OTC options diminish long-term prospects.
• Therapeutic Innovations: Development of novel ED therapies and delivery systems may further overshadow STAXYN.

Estimated revenue decline to near zero within the next 2-3 years unless the manufacturer introduces new formulations or indications.

---

Strategic Considerations

• Repositioning or Line Extensions: Potential to develop combination therapies or new delivery mechanisms.
• Geographical Markets: High growth potential in emerging markets with lower patent enforcement and less generic competition.
• Partnerships and Licensing: Opportunities for licensing generic versions or partnering for broader indications.

---

Key Takeaways

• STAXYN's initial success was limited by patent expiration and rapid erosion due to generic competition.
• Its revenue stream has diminished sharply, with minimal contributions expected moving forward.
• Quantity of market share lost to generics and broader ED treatment options renders STAXYN increasingly obsolete.
• Future prospects hinge on strategic repositioning, despite the challenging competitive environment.

---

Frequently Asked Questions

1. Why did STAXYN's market share decline rapidly after 2016?
Patent expiration allowed generics to enter, causing price reductions and shifting prescriber preference toward less expensive alternatives.

2. Are there recent developments to revive STAXYN's sales?
No significant recent innovations or indications have emerged; the product remains in decline without notable repositioning efforts.

3. How does STAXYN compare to other PDE5 inhibitors in efficacy?
Pharmacologically similar to other PDE5 inhibitors; differences lie mainly in formulation and onset time, but these do not provide sufficient competitive advantage post-generic entry.

4. What markets hold long-term potential for STAXYN?
Limited; emerging markets with less patent enforcement may offer niche opportunities, especially with targeted marketing.

5. What strategic options exist for pharmaceutical companies facing similar patent expirations?
Invest in new formulations, seek additional indications, form licensing agreements, or explore combination therapies to extend lifecycle.

---

References

[1] IQVIA, "Global Erectile Dysfunction Market Report," 2022.
[2] FDA, "Drug Approvals and Patent Status," 2007–2023.
[3] Evaluate Pharma, "PDE5 Inhibitors Market Analysis," 2022.